Postoperative Concurrent Chemoradiotherapy Followed by Anti-PD-1 Antibody Maintenance Therapy in High-Risk Locally Advanced Head and Neck Squamous Cell Carcinoma
Latest Information Update: 19 Dec 2023
At a glance
- Drugs Camrelizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Sintilimab (Primary) ; Tislelizumab (Primary) ; Toripalimab (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 19 Dec 2023 New trial record